Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001104659-13-027214
Filing Date
2013-04-05
Accepted
2013-04-05 06:01:09
Documents
6
Effectiveness Date
2013-04-05

Document Format Files

Seq Description Document Type Size
1 DEFA14A a13-1825_2defa14a.htm DEFA14A 37529
2 GRAPHIC g18252bci001.jpg GRAPHIC 47660
3 GRAPHIC g18252bci002.jpg GRAPHIC 84474
4 GRAPHIC g18252bci003.jpg GRAPHIC 33246
5 GRAPHIC g18252bci004.jpg GRAPHIC 25743
6 GRAPHIC g18252bci005.jpg GRAPHIC 13872
  Complete submission text file 0001104659-13-027214.txt   321834
Mailing Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922
Business Address 200 CONNELL DRIVE SUITE 1500 BERKELEY HEIGHTS NJ 07922 908-517-7330
Cyclacel Pharmaceuticals, Inc. (Filer) CIK: 0001130166 (see all company filings)

EIN.: 911766850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 000-50626 | Film No.: 13744270
SIC: 2834 Pharmaceutical Preparations